-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-305 in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-305 in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMG-305 in Cervical Cancer Drug Details: Monoclonal antibody is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lisavanbulin in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisavanbulin in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisavanbulin in Glioblastoma Multiforme (GBM) Drug Details: Lisavanbulin (BAL-101553) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Annamycin in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Annamycin in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Annamycin in Refractory Acute Myeloid Leukemia Drug Details: L-Annamycin is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Brexanolone in Essential Tremor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Brexanolone in Essential Tremor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Brexanolone in Essential Tremor Drug Details: Brexanolone is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AC-0676 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AC-0676 in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AC-0676 in Mantle Cell Lymphoma Drug Details: AC-0676 is under development...
-
Product Insights
Ocular Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ocular Melanoma - Drugs In Development, 2023’, provides an overview of the Ocular Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Thymoma (Thymic Epithelial Tumor) – Drugs In Development, 2023
Global Markets Direct’s, ‘Thymoma (Thymic Epithelial Tumor) - Drugs In Development, 2023’, provides an overview of the Thymoma (Thymic Epithelial Tumor) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thymoma (Thymic Epithelial Tumor), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Uveal Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Uveal Melanoma - Drugs In Development, 2023’, provides an overview of the Uveal Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...